Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Franklin Parlapiano Turner & Welch LLC

Franklin Parlapiano Turner & Welch LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 31,890 shares of the medical instruments supplier’s stock after acquiring an additional 1,061 shares during the period. Becton, Dickinson and Company makes up approximately 2.0% of Franklin Parlapiano Turner & Welch LLC’s holdings, making the stock its 19th largest holding. Franklin Parlapiano Turner & Welch LLC’s holdings in Becton, Dickinson and Company were worth $7,235,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sound Income Strategies LLC grew its stake in Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the last quarter. Central Pacific Bank Trust Division boosted its stake in Becton, Dickinson and Company by 22.5% during the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 45 shares in the last quarter. Tompkins Financial Corp boosted its position in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the period. Birch Capital Management LLC lifted its stake in Becton, Dickinson and Company by 0.4% in the 3rd quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock worth $2,838,000 after acquiring an additional 48 shares in the last quarter. Finally, Radnor Capital Management LLC lifted its stake in Becton, Dickinson and Company by 1.7% in the 3rd quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock worth $708,000 after acquiring an additional 48 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Down 0.9 %

Shares of BDX opened at $246.85 on Thursday. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $250.91. The stock has a market capitalization of $71.59 billion, a price-to-earnings ratio of 41.56, a PEG ratio of 1.72 and a beta of 0.39. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The stock has a fifty day moving average of $229.10 and a 200-day moving average of $233.46.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the company posted $3.42 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.42 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share repurchase plan on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.69%. Becton, Dickinson and Company’s payout ratio is 70.03%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the sale, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This trade represents a 15.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock valued at $2,210,716 in the last 90 days. 0.36% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler raised their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.